Nina Moeker

Company: Immatics

Job title: Vice President, Development Lead Preclinical Portfolio

Seminars:

ACTallo: An Engineered T-Cell Therapy Platform for Adoptive Cell Therapies 2:00 pm

Immatics develops TCR-based cancer immunotherapies by combining the discovery of naturally HLA-presented targets with the discovery of the right T-cell receptors T-cell receptor (TCR)-based immunotherapies hold a great potential for the treatment of solid tumors by targeting extra- and intracellular tumor-associated antigens For our allogeneic ACT platform, we employ CRISPR/Cas technology to introduce 1) targeted…Read more

day: Post-Conference Solid Tumor Focus Day